At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in its Lp(a) programme, treating Lp(a) lowering as a new cardiovascular growth area alongside its GLP-1 therapies. Eli Lilly highlighted elevated Lp(a) as a major unmet need within a broader cardiometabolic strategy that also includes obesity, diabetes, early Alzheimer’s disease and early breast cancer, and described the two programs as part of Lilly’s next innovation wave beyond its current incretin and amylin therapies.
Lepodisiran, an injectable siRNA, showed very strong and long-lasting Lp(a) reduction in Phase 2 ALPACA, with up to about 94% reduction at the highest dose and effects persisting for more than a year after a single administration, and is now in the ACCLAIM-Lp(a) Phase 3 trial to see if it can reduce major cardiovascular events. Muvalaplin, a first-in-class oral Lp(a) blocker, demonstrated Lp(a) reductions in the Phase 2 KRAKEN study following Phase I data showing up to roughly 65% reduction over 14 days, and Eli Lilly is positioning it as a more convenient long-term oral alternative to infrequent injections.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Eli Lilly is treating Lp(a) as a long-term cardiovascular growth pillar and has emphasised that most of its pipeline drugs now lie outside its core incretin/amylin programs, with Lp(a) a key example of its move into genetic and RNA-based medicines. The company is also helping build future demand by backing the Family Heart Foundation’s multi-year “Lp(a) AW(a)RE” and “Lp(a) Awareness to Action” efforts, which seek to raise physician and payer awareness, expand testing and promote at-home screening, steps that could facilitate uptake if lepodisiran and muvalaplin reach the market.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
